RxDoctor Payments Data

Amogechukwu Okonkwo, MD

Hospitalist · Syracuse, NYNPI 1053378612

Payments from drug & device makers

$281in general payments, 2019–2025

Across 9 payments — averaging $31.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avanir Pharmaceuticals, Inc.$99
  • AstraZeneca$86
  • AbbVie$20
  • Ironwood Pharmaceuticals, Inc$20
  • Acadia Pharmaceuticals Inc$15
  • Novo Nordisk$14
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$281100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Avanir Pharmaceuticals, Inc.1$99
AstraZeneca2$86
AbbVie1$20
Ironwood Pharmaceuticals, Inc1$20
Acadia Pharmaceuticals Inc1$15
Novo Nordisk1$14
Sentynl Therapeutics, Inc.1$14
GSK1$13

How this compares

$281 in reported general payments places this provider in the 70th percentile of 1,860 hospitalist providers in New York.

See all hospitalist providers in New York

Medicare billing

Part B allowed, 2024
$89,964
Medicare patients
406
Services billed
795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,176$350,628
IngrezzaValbenazine Tosylate66$256,930
NuplazidPimavanserin Tartrate42$72,374
Trelegy ElliptaFluticasone/Umeclidin/Vilanter89$61,226
OzempicSemaglutide46$46,841
RexultiBrexpiprazole56$46,306
XareltoRivaroxaban148$40,609
MyrbetriqMirabegron165$37,356
ZenpepLipase/Protease/Amylase14$35,405
MounjaroTirzepatide55$33,489
SantylCollagenase Clostridium Hist.74$31,752
TrulicityDulaglutide48$30,954
JardianceEmpagliflozin87$26,738
Invega SustennaPaliperidone Palmitate12$22,692
LinzessLinaclotide37$21,192

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$13$94,509171 claims
Acadia Pharmaceuticals IncNuplazid$15$72,37442 claims
Novo NordiskOzempic$14$46,84146 claims
AbbVieLinzess, Creon$20$41,39976 claims
AstraZenecaBreztri Aerosphere, Farxiga$86$13,46632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,860 hospitalist providers in New York.

Other hospitalist in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →